Marvel Biosciences Corp. develops novel therapies for autism spectrum disorder and related neurological and neurodevelopmental disorders through its wholly owned subsidiary, Marvel Biotechnology Inc. The company's lead therapeutic candidate, MB-204, is described as a fluorinated derivative of Istradefylline and an adenosine A2A receptor blocker.
Company news commonly covers MB-204 development, pediatric-friendly oral liquid formulation work, intellectual-property protection for purine compounds, scientific and partnering activity in neuroscience, and broader clinical or regulatory disclosures. Updates also reference potential disease areas tied to A2A receptor biology, including autism, depression, Alzheimer's disease, Rett syndrome and Fragile X syndrome, as well as capital-structure matters relevant to the public company.
Marvel Biosciences (MBCOF) has selected CMAX in Adelaide, Australia, as the Phase I clinical site for first-in-human testing of MB-204.
Marvel plans to begin with a single ascending dose study, testing progressively higher doses to evaluate safety, tolerability and how the drug moves through the body. The study is also expected to assess potential biomarkers and selected cognitive endpoints to inform a later multiple ascending dose study. Initiation remains subject to regulatory and ethics approvals and completion of clinical preparations.
Preclinical work reported behavioural and cognitive improvements in Rett, Fragile X and autism mouse models. The August 2026 Fragile X study showed statistically significant recognition-memory improvements at both tested doses, with persistent effects on selected endpoints after treatment ended. Preliminary Shank3 mouse findings showed behavioural improvements; final analyses and additional endpoints remained pending.
Marvel Biosciences (MBCOF) reported preliminary MB-204 results showing improvements in autism-related behaviours in a mouse model associated with Phelan-McDermid syndrome. The Shank3 study compared oral MB-204 doses of 1 mg/kg and 2.5 mg/kg with Istradefylline at 1 mg/kg. Low-dose MB-204 matched or exceeded the comparator on most measured endpoints; the higher dose was superior on most endpoints. MB-204 improved multiple behavioural measures versus untreated Shank3 mice.
Final statistical analyses and additional endpoints remain pending, and further analysis may change individual endpoint interpretations. Marvel views the findings, alongside earlier results in genetically distinct models, as support for evaluating MB-204's potential across neurodevelopmental disorders.
Marvel Biosciences (MBCOF) has signed a letter of intent with Novatech for the planned first-in-human Phase 1 trial of MB-204. The single ascending dose study, which tests increasing doses, is expected to begin in Q4 2026 in Australia. It will assess safety, tolerability and pharmacokinetics—how the body processes the drug—and include a potential biomarker and several cognitive endpoints. Its data will inform the subsequent multiple ascending dose study.
Marvel reports effects across Oprm1, Rett and Fragile X mouse models, including effects after treatment stopped. The company has recently closed a private placement and cites a 43% tax credit in Australia. Separately, Marvel plans an experiment with the iBrain Inserm Lab comparing MB-204 with Yamo Pharmaceuticals’ L1-79 in an autism mouse model. Marvel is also preparing manuscripts for scientific publication.
Marvel Biosciences (OTC: MBCOF, TSXV: MRVL) granted a total of 50,001 deferred share units (DSUs) to its three independent directors, in lieu of cash directors' fees. All DSUs will vest on September 1, 2027 and will be settled after each director separates from service, expiring 365 days thereafter. The deemed value of the DSUs was based on the August 31, 2026 VWAP of Marvel's common shares on the TSX Venture Exchange of $0.15 per share, multiplied by the number of DSUs awarded.
Marvel Biosciences (OTC: MBCOF, TSXV: MRVL) reported positive preclinical results showing its lead candidate MB-204 reversed behavioural and cognitive deficits in a Fragile X (Fmr1 knockout) mouse model, in a study run through the independent FRAXA Drug Validation Initiative in collaboration with FRAXA Research Foundation.
Oral low- and high-dose MB-204 given for two weeks improved all measured endpoints toward wild-type levels, with statistically significant effects in novel object recognition, open-field activity, self-grooming, nesting and hyponeophagia. High-dose animals showed wildtype-like patterns on several measures and demonstrated durable, though attenuated, carry-over benefits two weeks after treatment stopped. MB-204 has now generated efficacy data in three autism spectrum disorder models, supporting advancement toward clinical trials and potential positioning in multiple orphan neurological indications, including Rett syndrome, Oprm1 ASD and Fragile X syndromes.
Marvel Biosciences (OTC:MBCOF) announced that collaborator Dr. Jérôme Becker from the iBraiN Institute will present at the 3rd European Purine Meeting in Bordeaux, France, from July 1–3, 2026.
The talk will cover adenosine A2A receptors in autism and preclinical work on Marvel’s lead A2A antagonist MB-204, developed over a three-year collaboration, and highlight Marvel’s progress toward Phase 1 clinical studies.
Marvel Biosciences (OTC:MBCOF) received a notice of allowance for Australian patent application 2021235803 covering composition of matter for lead candidate MB-204. The patent, expected to be granted shortly after August 28, 2026, strengthens global IP as MB-204 advances toward Phase I trials.
According to Marvel, MB-204 has shown positive preclinical efficacy, including in Rett syndrome models versus trofinetide, and supports the company’s shift from pre-clinical research to clinical-stage development.
Marvel Biosciences (OTCQB:MBCOF) awarded 50,001 deferred share units (DSUs) to its three independent directors as payment in lieu of cash directors' fees. The DSUs vest on May 19, 2027, and their deemed value uses the $0.15 VWAP on May 19, 2026.
Marvel Biosciences (OTC:MBCOF) will present at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston on April 29, 2026 at 11:15 AM EST. The company highlighted its lead asset MB204, issued composition-of-matter patents in the US, Japan and China, and says non-dilutive funding supported completion of final preclinical studies and will fund a Phase 1 trial.
Marvel Biosciences (MBCOF) closed a non-brokered private placement of unsecured convertible debentures for gross proceeds of $500,000, subject to final TSXV approval.
The Debentures carry 12% annual interest payable in cash or common shares, mature on Dec 31, 2027, and convert at $0.17 per share. The company may force conversion if the VWAP reaches $0.60 for 10 consecutive trading days. Securities are subject to a hold period until Aug 17, 2026. Net proceeds will fund drug formulation, toxicology studies and general working capital.